According to Allogene Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5337.34. At the end of 2023 the company had a P/S ratio of > 1000.
Year | P/S ratio | Change |
---|---|---|
2023 | > 1000 | 52.32% |
2022 | > 1000 | 6656.85% |
2021 | 55.2 | |
2020 | N/A | |
2019 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |